Back to Trades
Buy4
Generate Biomedicines, Inc.
GENB
Total Value
$75.5M
Net $75.0M bought
Purchases
$75.0M
3 transactions
Company Information
- Company Name
- Generate Biomedicines, Inc.
- Ticker Symbol
- GENB
- CIK
- 0002100782
Insider Information
- Name
- AFEYAN NOUBAR
- Role
- Insider
- Location
- CAMBRIDGE, MA
Filing Details
- Filing Date
- Mar 2, 2026
- Transaction Date
- Feb 26, 2026
- Accession Number
- 0001193125-26-085855
- Form Type
- 4
- Net Trading Amount
- $75.0M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Common Stock | 12,723,940 | — | C | — |
| Mar 2, 2026 | Common Stock | 13,702,224 | — | C | — |
| Mar 2, 2026 | Common Stock | 987,491 | — | C | — |
| Mar 2, 2026 | Common Stock | 2,777,752 | — | C | — |
| Mar 2, 2026 | Common Stock | 2,777,752 | — | C | — |
| Mar 2, 2026 | Common Stock | 1,562,500 | $16.00 | Purchase | $25.0M |
| Mar 2, 2026 | Common Stock | 1,562,500 | $16.00 | Purchase | $25.0M |
| Mar 2, 2026 | Common Stock | 1,562,500 | $16.00 | Purchase | $25.0M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Feb 26, 2026 | Derivative | 29,561 | $16.00 | Grant/Award | $473.0K |
| Mar 2, 2026 | Derivative | 18,483,785 | — | C | — |
| Mar 2, 2026 | Derivative | 17,016,215 | — | C | — |
| Mar 2, 2026 | Derivative | 1,500,000 | — | C | — |
| Mar 2, 2026 | Derivative | 843,881 | — | C | — |
| Mar 2, 2026 | Derivative | 1,265,822 | — | C | — |
| Mar 2, 2026 | Derivative | 2,953,586 | — | C | — |
| Mar 2, 2026 | Derivative | 2,109,704 | — | C | — |
| Mar 2, 2026 | Derivative | 2,531,644 | — | C | — |
| Mar 2, 2026 | Derivative | 1,265,822 | — | C | — |
| Mar 2, 2026 | Derivative | 2,109,704 | — | C | — |
Footnotes
- (F1)Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
- (F2)Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date.
- (F3)Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
- (F4)Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
- (F5)Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
- (F6)Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
- (F7)Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
- (F8)Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
- (F9)The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.